These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26559049)

  • 1. Initiation of glucose-lowering treatment decreases international normalized ratio levels among users of vitamin K antagonists: a self-controlled register study.
    Stage TB; Pottegård A; Henriksen DP; Christensen MM; Højlund K; Brøsen K; Damkier P
    J Thromb Haemost; 2016 Jan; 14(1):129-33. PubMed ID: 26559049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoepidemiological assessment of drug interactions with vitamin K antagonists.
    Pottegård A; dePont Christensen R; Wang SV; Gagne JJ; Larsen TB; Hallas J
    Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1160-7. PubMed ID: 25250949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm.
    Beinema MJ; van der Meer FJ; Brouwers JR; Rosendaal FR
    J Thromb Haemost; 2016 Mar; 14(3):479-84. PubMed ID: 26712475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin use decreases the anticoagulant effect of phenprocoumon.
    Wijnen JC; van de Riet IR; Lijfering WM; van der Meer FJ
    J Thromb Haemost; 2014 Jun; 12(6):887-90. PubMed ID: 24698366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists.
    de Koning MLY; Fischer K; de Laat B; Huisman A; Ninivaggi M; Schutgens REG
    J Thromb Haemost; 2017 May; 15(5):868-875. PubMed ID: 28296129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches to optimal dosing of vitamin K antagonists.
    Witt DM
    Semin Thromb Hemost; 2012 Oct; 38(7):667-72. PubMed ID: 22893509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation of glucose-lowering drugs reduces the anticoagulant effect of warfarin-But not through altered drug metabolism in patients with type 2 diabetes.
    Dunvald AD; Nielsen F; Olsen DA; Ernst MT; Donnelly L; Soto-Pedre E; Kristiansen MR; Nielsen JS; Persson F; Højlund K; Madsen JS; Søndergaard J; Pearson E; Pottegård A; Stage TB
    Br J Clin Pharmacol; 2023 Aug; 89(8):2529-2541. PubMed ID: 36967527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of amiodarone on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population.
    Holm J; Lindh JD; Andersson ML; Mannheimer B
    J Thromb Haemost; 2017 Mar; 15(3):446-453. PubMed ID: 28058824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality control of oral anticoagulation with vitamin K antagonists in primary care patients in Poland: a multi-centre study.
    Sawicka-Powierza J; Buczkowski K; Chlabicz S; Gugnowski Z; Powierza K; Ołtarzewska AM
    Kardiol Pol; 2018; 76(4):764-769. PubMed ID: 29313558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
    Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
    J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin use decreases coagulation in users of vitamin K antagonists.
    van Rein N; Biedermann JS; Bonafacio SM; Kruip MJ; van der Meer FJ; Lijfering WM
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1441-1447. PubMed ID: 27709253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Point-of-care testing and INR within-subject variation in patients receiving a constant dose of vitamin K antagonist.
    van den Besselaar AM; Biedermann JS; Kruip MJ
    Thromb Haemost; 2015 Nov; 114(6):1260-7. PubMed ID: 26202616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists.
    van Rein N; Lijfering WM; Bos MH; Herruer MH; Vermaas HW; van der Meer FJ; Reitsma PH
    PLoS One; 2016; 11(12):e0164485. PubMed ID: 27935941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Ansell J; Hirsh J; Poller L; Bussey H; Jacobson A; Hylek E
    Chest; 2004 Sep; 126(3 Suppl):204S-233S. PubMed ID: 15383473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Body Weight on Dose of Vitamin K Antagonists.
    Self TH; Wallace JL; Sakaan S; Sands CW
    South Med J; 2015 Oct; 108(10):637-43. PubMed ID: 26437201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-drug interactions between vitamin K antagonists and statins: a systematic review.
    Engell AE; Svendsen ALO; Lind BS; Stage TB; Hellfritzsch M; Pottegård A
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1435-1441. PubMed ID: 33895864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists.
    Visser C; Biedermann JS; Nierman MC; van der Meer FJM; Gulpen AJW; Moors YCF; Cannegieter SC; Lijfering WM; Kruip MJHA;
    Thromb Haemost; 2022 Mar; 122(3):377-385. PubMed ID: 35245945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
    Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
    Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive procedures in the outpatient setting: managing the short-acting acenocoumarol and the long-acting phenprocoumon.
    van Geest-Daalderop JH; Hutten BA; Péquériaux NC; de Vries-Goldschmeding HJ; Räkers E; Levi M
    Thromb Haemost; 2007 Oct; 98(4):747-55. PubMed ID: 17938797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.